Literature DB >> 33654788

Fluorescence HPLC Analysis of the in-vivo Activity of Glucosylceramide Synthase.

Kartik R Roy1, Sachin K Khiste1, Zhijun Liu2, Yong-Yu Liu1.   

Abstract

Almost all functions of cells or organs rely on the activities of cellular enzymes. Indeed, the in-vivo activities that directly represent the cellular effects of enzymes in live organs are critical importance to appreciate the roles enzymes play in modulating physiological or pathological processes, although assessments of such in-vivo enzyme activity are more difficult than typical test-tube assays. Recently, we, for the first time, developed a direct and easy-handling method for HPLC analyzing the in-vivo activity of glucosylceramide synthase (GCS). GCS that converts ceramide into glucosylceramide is a limiting-enzyme in the syntheses of glycosphingolipids and is one cause of cancer drug resistance. In our method developed, rubusoside nanomicelles delivers fluorescence N-[6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl]-d-erythro-sphingosine (NBD C6-ceramide) into mice, tissues uptake the cell-permeable substrate, and GCS converts it into NBD C6-glucosylceramide in all organs simultaneously. Further, HPLC analyzes the extracted NBD C6-glucosylceramide to assess alterations of the in-vivo GCS activities in tissues. This method can be broadly used to assess the in-vivo GCS activities in any kind of animal models to appreciate either the role GCS plays in diseases or the therapeutic efficacies of GCS inhibitors.
Copyright © 2019 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Cancer; Ceramide; Fluorescence NBD; Glucosylceramide synthase; High-performance liquid chromatography; In-vivo enzyme activity ; Nanomicelles; Rubusoside

Year:  2019        PMID: 33654788      PMCID: PMC7854238          DOI: 10.21769/BioProtoc.3269

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  30 in total

Review 1.  The glycosynapse.

Authors:  Sen-itiroh Hakomori Si
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

2.  Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.

Authors:  Y Lavie; H t Cao; A Volner; A Lucci; T Y Han; V Geffen; A E Giuliano; M C Cabot
Journal:  J Biol Chem       Date:  1997-01-17       Impact factor: 5.157

3.  Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain.

Authors:  S Basu; B Kaufman; S Roseman
Journal:  J Biol Chem       Date:  1968-11-10       Impact factor: 5.157

4.  A sensitive and reproducible assay to measure the activity of glucosylceramide synthase and lactosylceramide synthase using HPLC and fluorescent substrates.

Authors:  Yasuhiro Hayashi; Yasuhiro Horibata; Keishi Sakaguchi; Nozomu Okino; Makoto Ito
Journal:  Anal Biochem       Date:  2005-06-13       Impact factor: 3.365

5.  Ceramide glycosylation potentiates cellular multidrug resistance.

Authors:  Y Y Liu; T Y Han; A E Giuliano; M C Cabot
Journal:  FASEB J       Date:  2001-03       Impact factor: 5.191

Review 6.  Role of glycosphingolipid-enriched microdomains in innate immunity: microdomain-dependent phagocytic cell functions.

Authors:  Fumiko Yoshizaki; Hitoshi Nakayama; Chihiro Iwahara; Kenji Takamori; Hideoki Ogawa; Kazuhisa Iwabuchi
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 7.  The role of glycosphingolipid metabolism in the developing brain.

Authors:  Robert K Yu; Yoshihiko Nakatani; Makoto Yanagisawa
Journal:  J Lipid Res       Date:  2008-10-09       Impact factor: 5.922

8.  Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase.

Authors:  Vineet Gupta; Gauri A Patwardhan; Qian-Jin Zhang; Myles C Cabot; S Michal Jazwinski; Yong-Yu Liu
Journal:  J Lipid Res       Date:  2009-10-13       Impact factor: 5.922

9.  A role for ceramide in driving cancer cell resistance to doxorubicin.

Authors:  Yong-Yu Liu; Jing Yuan Yu; Dongmei Yin; Gauri Anand Patwardhan; Vineet Gupta; Yoshio Hirabayashi; Walter M Holleran; Armando E Giuliano; S Michal Jazwinski; Valerie Gouaze-Andersson; David P Consoli; Myles C Cabot
Journal:  FASEB J       Date:  2008-02-01       Impact factor: 5.191

10.  Incorporation of Fluorescence Ceramide-Based HPLC Assay for Rapidly and Efficiently Assessing Glucosylceramide Synthase In Vivo.

Authors:  Sachin K Khiste; Salman B Hosain; Yixuan Dong; Mohammad B Uddin; Kartik R Roy; Ronald A Hill; Zhijun Liu; Yong-Yu Liu
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.